Skip to main content
Atlanta Poland S.A. logo

Atlanta Poland S.A. — Investor Relations & Filings

Ticker · ATP ISIN · PLATLPL00018 LEI · 259400I5IEBCZXNAHG46 WAR Manufacturing
Open in API
Filings indexed 714 across all filing types
Latest filing 2025-03-31 Audit Report / Informat…
Country PL Poland
Listing WAR ATP

About Atlanta Poland S.A.

https://atlantapoland.com.pl/

Atlanta Poland S.A. is a company specializing in the import, processing, packaging, and distribution of nuts and dried fruits. It is a major supplier of raw materials to the confectionery and bakery industries. The company's operations also extend to wholesale and retail markets, managing the value chain from sourcing and importing to the final sale of its products.

Recent filings

Filing Released Lang Actions
Sprawozdanie_finansowe
Audit Report / Information Classification · 98% confidence The document text is in Polish and contains a detailed table of contents listing various financial statements and notes, such as 'SPRAWOZDANIE Z SYTUACJI FINANSOWEJ' (Statement of Financial Position), 'SPRAWOZDANIE Z CAŁKOWITYCH DOCHODÓW' (Statement of Comprehensive Income), 'SPRAWOZDANIE Z PRZEPŁYWÓW PIENIĘŻNYCH' (Statement of Cash Flows), and extensive notes covering accounting policies, assets, liabilities, and equity. Furthermore, the table at the end shows comparative figures for 'Stan na 31.12.2024r.' (As of 31.12.2024) and 'Stan na 30.06.2024r.' (As of 30.06.2024), indicating a comprehensive financial report covering a period shorter than a full year (half-year or interim period, given the June date). This structure strongly aligns with an Interim/Quarterly Report (IR), rather than a full Annual Report (10-K) or just an Earnings Release (ER). H1 2024
2025-03-31 Polish
Sprawozdanie_Zarządu
Interim / Quarterly Report Classification · 100% confidence The document is a 'Sprawozdanie Zarządu z działalności' (Management Board Report on Activities) for Atlanta Poland S.A. for the first half of the 2024/2025 fiscal year. It contains comprehensive financial statements, including the balance sheet, income statement, cash flow statement, and detailed management commentary on financial performance, market trends, and operational results. Since it covers a period shorter than a full fiscal year (six months) and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2024
2025-03-31 Polish
Podpisanie przez spółkę zależną umowy dotyczącej stałych dostaw marihuany medycznej zarejestrowanej w Polsce. - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is in Polish and discusses a contract signed by a subsidiary ('thc Pharma S.A.') for the supply of medical marijuana, detailing the expected value (4.2 million PLN in 2025) and its potential impact on the Group's results. It also mentions import permits and supply chain optimization. This content relates to significant business operations, supply agreements, and financial outlook, but it is not a formal financial statement (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific operational update concerning a major contract. Since it details a significant business transaction and its financial implications, it fits best under a general regulatory announcement or a specific business update. Given the options, it is a significant business development announcement. It is too specific for RNS (the fallback) and doesn't fit ER, IR, or MDA perfectly. However, major contract signings that significantly impact future revenue are often classified as material event disclosures. In the absence of a specific 'Material Event Disclosure' code, and considering it's a detailed operational update rather than a simple announcement of a report, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the contract was tied to financing, which it isn't explicitly. Given the nature of reporting material operational changes, RNS is the most appropriate general category for non-standard, material disclosures not covered by other specific codes like DIV or DIRS. The document length is short (1457 chars), but it contains the substance of the news, not just an announcement of an attachment, thus avoiding the RPA classification.
2025-03-12 Polish
Podpisanie przez spółkę zależną umowy dotyczącej stałych dostaw marihuany medycznej zarejestrowanej w Polsce.
M&A Activity Classification · 99% confidence The document is a formal announcement by the Management Board of Cannabis Poland S.A. regarding a significant contract signed by its subsidiary, 'thc Pharma S.A.', for the supply of medical marijuana. The contract value is estimated to be at least 4.2 million PLN in 2025, which is expected to significantly impact the Group's results. This type of announcement, detailing a major business agreement, contract signing, or significant operational development that impacts future financial performance, aligns best with the description of a general regulatory announcement or a material event disclosure. Since it is not a standard financial report (10-K, IR, ER), a management discussion (MDA), or a specific financing event (CAP), it falls under the general category for material regulatory disclosures. Given the context of Polish regulatory filings, this is a material event disclosure. In the provided schema, the closest fit for a significant, non-standard material event disclosure that isn't explicitly covered by other codes (like DIRS, DIV, MANG) is the general 'Regulatory Filings' (RNS) or potentially 'Capital/Financing Update' (CAP) if the contract was viewed as securing future revenue streams, but 'RNS' is the most appropriate fallback for material, non-standard corporate news. However, upon re-evaluation against the definitions, this document details a major commercial agreement and its expected financial impact. It is a disclosure of a material contract. If this were a US filing, it might be an 8-K Item 1.01 (Entry into a Material Definitive Agreement). Among the provided codes, 'RNS' (Regulatory Filings - general fallback) is the safest choice, as it is a material disclosure not fitting other specific categories like M&A (TAR) or Financing (CAP). The document length (1431 chars) is short, but it contains the substance of the event, not just an announcement *about* a report, so RPA is incorrect. Therefore, RNS is selected as the best fit for a material corporate event disclosure.
2025-03-12 Polish
Zawarcie aneksu na wyłączność do umowy z dostawcą marihuany medycznej Cannabis flos 20% THC - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is a formal announcement from the Management Board (Zarząd) of Cannabis Poland S.A. (Emitent) referencing a previous report (31/2024). It details the signing of an annex to a supply agreement, specifically concerning exclusivity clauses, penalties for breach, and expectations regarding stability testing and regulatory registration timelines (Q1 and Q3). This content relates to ongoing business operations, supply chain security, and regulatory progress, which falls under general business updates or management commentary rather than a specific financial report (like 10-K or IR), a dividend announcement, or a director's dealing. Since it is a specific operational update concerning supply contracts and regulatory steps, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the more specific categories like CAP (financing), LTR (legal), or MDA (detailed financial management report). Given the short length and the nature of providing an update on operational milestones, RNS is the most appropriate fallback.
2025-02-11 Polish
Zawarcie aneksu na wyłączność do umowy z dostawcą marihuany medycznej Cannabis flos 20% THC
Regulatory Filings Classification · 100% confidence The document is a formal announcement by the Management Board (Zarząd) of Cannabis Poland S.A. regarding an amendment (aneks) to a supply agreement for cannabis raw material. It details the exclusivity terms of the agreement, mentions expected future agreements (stability testing, pharmaceutical production), and outlines the business rationale and regulatory necessity (stability testing for registration). This content focuses on operational agreements, supply chain stability, and regulatory milestones, which are key aspects of business strategy and ongoing operations. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a director's dealing report (DIRS). It is too specific for a general Regulatory Filing (RNS) and doesn't fit the definitions for M&A (TAR) or Capital changes (CAP). Given the focus on operational agreements securing supply and competitive advantage, it aligns best with general business updates that often fall under Management Discussion/Analysis or strategic operational announcements. Since there is no specific category for 'Supply Chain/Operational Update,' and it details management's view on securing stability and competitive advantage, it is closest to Management Reports (MDA) or potentially a general Regulatory Filing (RNS). However, because it details specific operational steps and strategic positioning following a previous report, MDA is a strong fit, describing management's view on business trends and outlook related to supply. Given the context of Polish regulatory filings, this type of operational update often accompanies or precedes formal financial reporting sections, making MDA the most appropriate fit among the provided options for strategic operational news.
2025-02-11 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.